The Effects of the Selective Serotonin Reuptake Inhibitor, Fluoxetine and/or DHEA, on Neuroendocrine, Autonomic Nervous System and Metabolic Counterregulatory Responses During Repeated Hypoglycemia in T1DM Individuals
Phase of Trial: Phase 0
Latest Information Update: 15 Jan 2018
At a glance
- Drugs Fluoxetine (Primary) ; Prasterone (Primary)
- Indications Depression
- Focus Pharmacodynamics
- 09 Jan 2018 Status changed from not yet recruiting to recruiting.
- 24 Oct 2017 Planned initiation date changed from 10 Oct 2017 to 11 Dec 2017.
- 27 Jul 2017 New trial record